Key points are not available for this paper at this time.
Many advanced prostate cancer patients receiving anti-androgens (Enzalutamide) as the first line of treatment, develop resistance which relapses into metastatic castrate-resistant prostate cancer (mCRPC). Treatment options for mCRPC patients are limited and continue to pose a significant oncological challenge with an alarming low survival rate of only 28%. The overarching goal of this research is thus to develop personalized metabolic imaging modality to target treatment strategies of different metabolic sub-types of prostate cancer by targeting pyruvate-to-lactate metabolism by hyperpolarized 1-13C-pyruvate MR and fatty acid oxidation by 18F-FPIA PET.
Enriquez et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: